Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

1.

Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis.

Westhovens R, Robles M, Ximenes AC, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Murthy B.

Ann Rheum Dis. 2015 Mar;74(3):564-8. doi: 10.1136/annrheumdis-2014-206149. Epub 2014 Dec 30.

PMID:
25550337
[PubMed - in process]
Free Article
2.

Therapeutic Vaccination with TNF-Kinoid in TNF Antagonist-Resistant Rheumatoid Arthritis: A Phase II Randomized, Controlled Clinical Trial.

Durez P, Vandepapeliere P, Miranda P, Toncheva A, Berman A, Kehler T, Mociran E, Fautrel B, Mariette X, Dhellin O, Fanget B, Ouary S, Grouard-Vogel G, Boissier MC.

PLoS One. 2014 Dec 17;9(12):e113465. doi: 10.1371/journal.pone.0113465. eCollection 2014.

PMID:
25517733
[PubMed - in process]
Free PMC Article
3.

Further international adaptation and validation of the Rheumatoid Arthritis Quality of Life (RAQoL) questionnaire.

Wilburn J, McKenna SP, Twiss J, Rouse M, Korkosz M, Jancovic R, Nemec P, Pacheco-Tena CF, Saraux A, Westhovens R, Durez P, Martin M, Tammaru M.

Rheumatol Int. 2014 Oct 1. [Epub ahead of print]

PMID:
25270915
[PubMed - as supplied by publisher]
4.

Assessment of activity limitations with the health assessment questionnaire predicts the need for support measures in patients with rheumatoid arthritis: a multicenter observational study.

Janssens X, Decuman S, De Keyser F; Belgian Rheumatoid Arthritis Disability Assessment Study Group.

PLoS One. 2014 Sep 4;9(9):e106749. doi: 10.1371/journal.pone.0106749. eCollection 2014.

PMID:
25188388
[PubMed - in process]
Free PMC Article
5.

Longterm followup of rituximab therapy in patients with rheumatoid arthritis: results from the Belgian MabThera in Rheumatoid Arthritis registry.

De Keyser F, Hoffman I, Durez P, Kaiser MJ, Westhovens R; MIRA Study Group.

J Rheumatol. 2014 Sep;41(9):1761-5. doi: 10.3899/jrheum.131279. Epub 2014 Aug 15.

PMID:
25128506
[PubMed - in process]
6.

Ten-year followup of infliximab therapy in rheumatoid arthritis patients with severe, longstanding refractory disease: a cohort study.

De Keyser F, De Kock J, Leroi H, Durez P, Westhovens R; Infliximab EAP Study Group.

J Rheumatol. 2014 Jul;41(7):1276-81. doi: 10.3899/jrheum.131270. Epub 2014 Jun 1.

PMID:
24882838
[PubMed - indexed for MEDLINE]
7.

Patient and physician expectations of add-on treatment with golimumab for rheumatoid arthritis: relationships between expectations and clinical and quality of life outcomes.

Dasgupta B, Combe B, Louw I, Wollenhaupt J, Zerbini CA, Beaulieu A, Schulze-Koops H, Durez P, Wolff V, Yao R, Weng HH, Govoni M, Vastesaeger N.

Arthritis Care Res (Hoboken). 2014 Dec;66(12):1799-807. doi: 10.1002/acr.22371.

PMID:
24839031
[PubMed - indexed for MEDLINE]
8.

Predictive value of ACR core set parameters for the development of rheumatoid arthritis in patients with positive anti-cyclic citrullinated peptide antibodies and undifferentiated arthritis.

Meric de Bellefon L, Houssiau F, Depresseux G, Nzeusseu Toukap A, Lauwerys B, Durez P.

Rheumatology (Oxford). 2014 Jul;53(7):1347-8. doi: 10.1093/rheumatology/keu160. Epub 2014 May 8. No abstract available.

PMID:
24811973
[PubMed - indexed for MEDLINE]
9.

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

Genovese MC, Fleischmann R, Furst D, Janssen N, Carter J, Dasgupta B, Bryson J, Duncan B, Zhu W, Pitzalis C, Durez P, Kretsos K.

Ann Rheum Dis. 2014 Sep;73(9):1607-15. doi: 10.1136/annrheumdis-2013-204760. Epub 2014 Mar 18.

PMID:
24641941
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

Genovese MC, Tena CP, Covarrubias A, Leon G, Mysler E, Keiserman M, Valente R, Nash P, Simon-Campos JA, Box J, Legerton CW 3rd, Nasonov E, Durez P, Delaet I, Teng J, Alten R.

J Rheumatol. 2014 Apr;41(4):629-39. doi: 10.3899/jrheum.130112. Epub 2014 Mar 1.

PMID:
24584926
[PubMed - indexed for MEDLINE]
Free Article
11.

Myeloperoxidase and its products in synovial fluid of patients with treated or untreated rheumatoid arthritis.

Nzeusseu Toukap A, Delporte C, Noyon C, Franck T, Rousseau A, Serteyn D, Raes M, Vanhaeverbeek M, Moguilevsky N, Nève J, Vanhamme L, Durez P, Van Antwerpen P, Zouaoui Boudjeltia K.

Free Radic Res. 2014 Apr;48(4):461-5. doi: 10.3109/10715762.2014.886327. Epub 2014 Feb 20.

PMID:
24460011
[PubMed - indexed for MEDLINE]
12.

Global molecular effects of tocilizumab therapy in rheumatoid arthritis synovium.

Ducreux J, Durez P, Galant C, Nzeusseu Toukap A, Van den Eynde B, Houssiau FA, Lauwerys BR.

Arthritis Rheumatol. 2014 Jan;66(1):15-23. doi: 10.1002/art.38202.

PMID:
24449571
[PubMed - indexed for MEDLINE]
13.

One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.

Genovese MC, Durez P, Richards HB, Supronik J, Dokoupilova E, Aelion JA, Lee SH, Codding CE, Kellner H, Ikawa T, Hugot S, Ligozio G, Mpofu S.

J Rheumatol. 2014 Mar;41(3):414-21. doi: 10.3899/jrheum.130637. Epub 2014 Jan 15.

PMID:
24429175
[PubMed - indexed for MEDLINE]
14.

Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial.

Smolen JS, Emery P, Fleischmann R, van Vollenhoven RF, Pavelka K, Durez P, Guérette B, Kupper H, Redden L, Arora V, Kavanaugh A.

Lancet. 2014 Jan 25;383(9914):321-32. doi: 10.1016/S0140-6736(13)61751-1. Epub 2013 Oct 26. Erratum in: Lancet. 2014 Jan 25;383(9914):308.

PMID:
24168956
[PubMed - indexed for MEDLINE]
15.

Construction and psychometric properties of the Belgian Rheumatoid Arthritis Disability Assessment (BRADA) questionnaire: a new tool for the evaluation of activity limitations in patients with rheumatoid arthritis.

Janssens X, Decuman S, De Keyser F; Brada I study group.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):596-605. Epub 2013 Jul 30.

PMID:
23899969
[PubMed - indexed for MEDLINE]
16.

Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

Emery P, Fleischmann RM, Doyle MK, Strusberg I, Durez P, Nash P, Amante E, Churchill M, Park W, Pons-Estel B, Xu W, Xu S, Wu Z, Hsia EC.

Arthritis Care Res (Hoboken). 2013 Nov;65(11):1732-42.

PMID:
23861303
[PubMed - indexed for MEDLINE]
17.

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study.

Combe B, Dasgupta B, Louw I, Pal S, Wollenhaupt J, Zerbini CA, Beaulieu AD, Schulze-Koops H, Durez P, Yao R, Vastesaeger N, Weng HH; GO-MORE Investigators.

Ann Rheum Dis. 2014 Aug;73(8):1477-86. doi: 10.1136/annrheumdis-2013-203229. Epub 2013 Jun 5.

PMID:
23740226
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

Smolen JS, Nash P, Durez P, Hall S, Ilivanova E, Irazoque-Palazuelos F, Miranda P, Park MC, Pavelka K, Pedersen R, Szumski A, Hammond C, Koenig AS, Vlahos B.

Lancet. 2013 Mar 16;381(9870):918-29. doi: 10.1016/S0140-6736(12)61811-X. Epub 2013 Jan 17.

PMID:
23332236
[PubMed - indexed for MEDLINE]
19.

Oral administration of GLPG0259, an inhibitor of MAPKAPK5, a new target for the treatment of rheumatoid arthritis: a phase II, randomised, double-blind, placebo-controlled, multicentre trial.

Westhovens R, Keyser FD, Rekalov D, Nasonov EL, Beetens J, Van der Aa A, Wigerinck P, Namour F, Vanhoutte F, Durez P.

Ann Rheum Dis. 2013 May;72(5):741-4. doi: 10.1136/annrheumdis-2012-202221. Epub 2012 Nov 17.

PMID:
23161899
[PubMed - indexed for MEDLINE]
20.

Impact of intravenous abatacept on synovitis, osteitis and structural damage in patients with rheumatoid arthritis and an inadequate response to methotrexate: the ASSET randomised controlled trial.

Conaghan PG, Durez P, Alten RE, Burmester GR, Tak PP, Klareskog L, Catrina AI, DiCarlo J, Gaillez C, Le Bars M, Zhou X, Peterfy C.

Ann Rheum Dis. 2013 Aug;72(8):1287-94. doi: 10.1136/annrheumdis-2012-201611. Epub 2012 Aug 21.

PMID:
22915624
[PubMed - indexed for MEDLINE]
Free PMC Article
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk